Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Antman, E.M.
Right arrow Articles by Jaffe, A.S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Antman, E.M.
Right arrow Articles by Jaffe, A.S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Issues in early risk stratification for UA/NSTEMI

E.M. Antman*,1, R. Corbalán2, K. Huber3 and A.S. Jaffe4

1 Brigham and Women's Hospital, Boston, Massachusetts, USA
2 Catholic University Hospital, Santiago, Chile
3 University of Vienna, Vienna, Austria
4 Mayo Clinic, Rochester, Minnesota, USA

* Correspondence: Elliott M, Antman, Brigham and Women's Hospital, Boston, Massachusetts, USA

Abstract

North American and European task forces representing the ACC/AHA and the ESC have recently developed new treatment guidelines for the management of unstable angina (UA) and non-ST-segment elevation myocardial infarction (NSTEMI). At the 4th Annual Experts' Meeting of the International Cardiology Forum, workshops were held to review the new recommendations. In the discussion of risk stratification, the most debated topic was the role assigned to the cardiac-specific troponins (cTnI and cTnT). Although the importance of these indicators in an integrated risk stratification scheme was well accepted, some participants felt that they received undue emphasis in the new guidelines, and the implication that troponin status should determine use of a glycoprotein IIb/IIIa inhibitor and early catheterization was debated. The value of continuous versus serial ECG monitoring was also discussed, but no consensus was reached. Although many were encouraged by the data on C-reactive protein (CRP) as a prognostic indicator, it was generally agreed that it is too soon to recommend its routine measurement in ACS. Finally, risk stratification is a complex, ongoing process that is impossible to reduce to a simple treatment algorithm.

Key Words: Unstable angina • risk stratification • troponins • guidelines


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.